肝细胞癌的肝移植：扩大标准是否合理？

Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?

作者信息

Roayaie Sasan, Llovet Josep M

机构信息

Division of Liver Diseases and Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

出版信息

Clin Liver Dis. 2005 May;9(2):315-28. doi: 10.1016/j.cld.2004.12.007.

DOI:10.1016/j.cld.2004.12.007

PMID:15831276

Abstract

Hepatocellular carcinoma (HCC) is a major health problem worldwide, involving more than a half million new cases yearly, with an age-adjusted incidence of 5.5 to 14.9 per 10(5) population. In some areas of Asia and the Middle East, HCC ranks as the first cause of death due to cancer. The incidence of HCC is increasing in Europe and the United States, and it is currently the leading cause of death among cirrhotic patients. It is estimated that by the year 2010, the number of patients with HCC awaiting liver transplant in the United States will outnumber the supply of cadaver organs.

摘要

肝细胞癌（HCC）是一个全球性的重大健康问题，每年新增病例超过50万，年龄调整发病率为每10（5）人口5.5至14.9例。在亚洲和中东的一些地区，HCC是癌症致死的首要原因。HCC在欧洲和美国的发病率正在上升，目前是肝硬化患者的主要死因。据估计，到2010年，美国等待肝移植的HCC患者数量将超过尸体器官的供应量。